{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:42:17Z","timestamp":1790844137714,"version":"4.1.0"},"reference-count":24,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2011.0635","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:20:20Z","timestamp":1525238420000},"source":"Crossref","is-referenced-by-count":17,"title":["Ovarian Cancer"],"prefix":"10.3238","author":[{"given":"Alexander","family":"Burges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schmalfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2011,9,23]]},"reference":[{"key":"10.3238\/arztebl.2011.0635_ref1","unstructured":"Krebs in Deutschland 2003 \u2013 2004. H\u00e4ufigkeiten und Trends. 6th revised edition. Robert-Koch-Institut (ed.) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (ed.). Berlin 2008."},{"key":"10.3238\/arztebl.2011.0635_ref2","unstructured":"Heintz AP, et al.: Carcinoma of the ovary. FIGO 6th anual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006; 95 (Suppl 1): 161\u201392."},{"key":"10.3238\/arztebl.2011.0635_ref3","doi-asserted-by":"crossref","unstructured":"du Bois A, Rochon J, Lamparter C, Pfisterer J f\u00fcr die AGO-Organkommission Ovar: Ovarialkarzinom \u2013 Versorgungsstruktur und -qualit\u00e4t in Deutschland 2001\u20132004. Der Frauenarzt 2005; 46(7): 60\u2013567.","DOI":"10.1055\/s-2005-836289"},{"key":"10.3238\/arztebl.2011.0635_ref4","doi-asserted-by":"crossref","unstructured":"Partridge E, et al.: Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009; 113(4): 775\u201382.","DOI":"10.1097\/AOG.0b013e31819cda77"},{"key":"10.3238\/arztebl.2011.0635_ref5","doi-asserted-by":"crossref","unstructured":"Rebbeck TR, Kauff ND, Domchek SM: Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101(2): 80\u20137.","DOI":"10.1093\/jnci\/djn442"},{"key":"10.3238\/arztebl.2011.0635_ref6","doi-asserted-by":"crossref","unstructured":"Kauff ND, et al.: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008; 26(8): 1331\u20137.","DOI":"10.1200\/JCO.2007.13.9626"},{"key":"10.3238\/arztebl.2011.0635_ref7","doi-asserted-by":"crossref","unstructured":"Casey MJ, et al.: Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol 2005; 97(2): 457\u201367.","DOI":"10.1016\/j.ygyno.2005.01.039"},{"key":"10.3238\/arztebl.2011.0635_ref8","doi-asserted-by":"crossref","unstructured":"Olivier RI, et al.: Clinical outcome of prophylactic oophorectomy in BRCA1\/BRCA2 mutation carriers and events during follow-up. Br J Cancer 2004; 90(8): 1492\u20137.","DOI":"10.1038\/sj.bjc.6601692"},{"key":"10.3238\/arztebl.2011.0635_ref9","doi-asserted-by":"crossref","unstructured":"Collaborative Group on Epidemiological Studies of Ovarian Cancer, ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 2008; (371): 303\u201314.","DOI":"10.1016\/S0140-6736(08)60167-1"},{"key":"10.3238\/arztebl.2011.0635_ref10","doi-asserted-by":"crossref","unstructured":"Morch LS, et al.: Hormone therapy and ovarian cancer. JAMA 2009; 302(3): 298\u2013305.","DOI":"10.1001\/jama.2009.1052"},{"key":"10.3238\/arztebl.2011.0635_ref11","doi-asserted-by":"crossref","unstructured":"Kinkel K, et al.: Indeterminate ovarian mass at US: incremental value of second imaging test for characterization \u2013 meta-analysis and Bayesian analysis. Radiology 2005; 236(1): 85\u201394.","DOI":"10.1148\/radiol.2361041618"},{"key":"10.3238\/arztebl.2011.0635_ref12","doi-asserted-by":"crossref","unstructured":"Salani R, et al.: Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 2008; 108(2): 271\u20135.","DOI":"10.1016\/j.ygyno.2007.11.004"},{"key":"10.3238\/arztebl.2011.0635_ref13","doi-asserted-by":"crossref","unstructured":"du Bois A, et al.: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer 2009; 115(6): 1234\u201344.","DOI":"10.1002\/cncr.24149"},{"key":"10.3238\/arztebl.2011.0635_ref14","doi-asserted-by":"crossref","unstructured":"Trimbos JB, et al.: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 2003; 95(2): 113\u201325.","DOI":"10.1093\/jnci\/95.2.113"},{"key":"10.3238\/arztebl.2011.0635_ref15","doi-asserted-by":"crossref","unstructured":"Bristow RE, et al.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20(5): 1248\u201359.","DOI":"10.1200\/JCO.2002.20.5.1248"},{"key":"10.3238\/arztebl.2011.0635_ref16","doi-asserted-by":"crossref","unstructured":"Eisenhauer EL, et al.: The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 2006; 103(3): 1083\u201390.","DOI":"10.1016\/j.ygyno.2006.06.028"},{"key":"10.3238\/arztebl.2011.0635_ref17","doi-asserted-by":"crossref","unstructured":"Aletti GD, et al.: Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 2006; 100(2): 283\u20137.","DOI":"10.1016\/j.ygyno.2005.08.027"},{"key":"10.3238\/arztebl.2011.0635_ref18","doi-asserted-by":"crossref","unstructured":"Bristow RE, et al.: Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999; 72(3): 278\u201387.","DOI":"10.1006\/gyno.1998.5145"},{"key":"10.3238\/arztebl.2011.0635_ref19","doi-asserted-by":"crossref","unstructured":"Dowdy SC, et al.: Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. Gynecol Oncol 2008; 109(2): 303\u20137.","DOI":"10.1016\/j.ygyno.2008.02.012"},{"key":"10.3238\/arztebl.2011.0635_ref20","doi-asserted-by":"crossref","unstructured":"Panici PB, et al.: Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005; 97(8): 560\u20136.","DOI":"10.1093\/jnci\/dji102"},{"key":"10.3238\/arztebl.2011.0635_ref21","doi-asserted-by":"crossref","unstructured":"Covens A, et al.: Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002; 85(1): 71\u201380.","DOI":"10.1006\/gyno.2001.6552"},{"key":"10.3238\/arztebl.2011.0635_ref22","doi-asserted-by":"crossref","unstructured":"Robinson WR, et al.: Clinical trial participation is associated with improved outcome in women with ovarian cancer. Int J Gynecol Cancer 2009; 19(1): 124\u20138.","DOI":"10.1111\/IGJ.0b013e31819a1ce8"},{"key":"10.3238\/arztebl.2011.0635_ref23","doi-asserted-by":"crossref","unstructured":"Piso P, Ghali N, Dahlke MH, et al.: Die intraoperative hypertherme intraperitoneale Chemotherapie als Therapieoption beim Ovarialkarzinom \u2013 Entwicklungen der letzten Jahre. Geburtshilfe und Frauenheilkunde 2007; 67(12): 1317\u201323.","DOI":"10.1055\/s-2007-989311"},{"key":"10.3238\/arztebl.2011.0635_ref24","doi-asserted-by":"crossref","unstructured":"du Bois A, Ewald-Riegler N, du Bois O, Harter P: Borderline tumors of the ovary \u2013 a systematic review. GebFra 2009; 69(9): 807\u201333.","DOI":"10.1055\/s-0029-1186007"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2011.0635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T09:56:32Z","timestamp":1638784592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2011.0635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,23]]},"references-count":24,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2011.0635","relation":{"is-cited-by":[{"id-type":"doi","id":"10.1155\/2015\/208017","asserted-by":"object"},{"id-type":"doi","id":"10.1155\/2016\/6845213","asserted-by":"object"}]},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,23]]}}}